FASS logotyp

Peka på symbolerna och beteckningarna till vänster för en förklaring.


Sök apotek med läkemedlet i lager

Sök lagerstatus



Filmdragerad tablett 5 mg/850 mg
(Bruna, bikonvexa, 9,5 x 20 mm ovala, filmdragerade tabletter med ”5/850” präglat på ena sidan och ”1067” präglat på andra sidan)

Diabetesmedel, Perorala blodglukossänkande medel, kombinationer

Aktiva substanser (i bokstavsordning):
ATC-kod: A10BD15
Läkemedel från AstraZeneca omfattas av Läkemedelsförsäkringen.
  • Vad är miljöinformation?




Miljörisk: Användning av dapagliflozin har bedömts medföra försumbar risk för miljöpåverkan.
Nedbrytning: Dapagliflozin bryts ned långsamt i miljön.
Bioackumulering: Dapagliflozin har låg potential att bioackumuleras.

Läs mer

Detaljerad miljöinformation

PEC/PNEC = 0.0032/100 = 3.2 x 10-5

PEC/PNEC ≤ 0.1

Environmental Risk Classification

Predicted Environmental Concentration (PEC)

PEC is based on following data and calculated using the equation outlined in the fass.se guidance (Ref 1):

PEC (µg/L) = (A*109*(100-R))/(365*P*V*D*100)

PEC (µg/L) = 1.37*10-6*A*(100-R)

A (kg/year) = 23.54 kg, total sold amount API in Sweden year 2020, data from IQVIA Health.

R (%) = removal rate (due to loss by adsorption to sludge particles, by volatilization,

hydrolysis or biodegradation) R = 0.

P = number of inhabitants in Sweden = 10 *106

V (L/day) = volume of wastewater per capita and day = 200 (default, Ref 1)

D = factor for dilution of waste water by surface water flow = 10 (default, Ref 1)

(Note: The factor 109 converts the quantity used from kg to μg).

PEC = 1.37 * 10-6 * 23.54 * (100-0) = 0.0032  μg/L

(Note: Whilst dapagliflozin is metabolised in humans, little is known about the ecotoxicity of the metabolites. Hence, as a worst case, for the purpose of this calculation, it is assumed that 100% of excreted metabolites have the same ecotoxicity as parent dapagliflozin).


Dapagliflozin is rapidly adsorbed and extensively metabolised. Dapagliflozin and its related metabolites are primarily eliminated via urinary excretion with less than 2% as unchanged dapagliflozin (Ref 2). After administration of a 50 mg [14C]-dapagliflozin dose, 96% was recovered, 75% in urine and 21% in faeces. In faeces, approximately 15% of the dose was excreted as parent drug (Ref 3). Therefore, the patient use of dapagliflozin is likely to result mainly in metabolites and, to a lesser extent, the active moiety entering the environment.

Ecotoxicity data

Study Type




Activated sludge, respiration inhibition test


3 h EC50 >200 mg/L

3 h NOEC = 200 mg/L


Toxicity to green algae, Pseudokirchinella subcapitata, growth inhibition test


72 hour NOECgrowth rate = 37 mg/L

72 hour LOECgrowth rate = 67 mg/L

72 hour EC50growth rate = 120 mg/L

72 hour NOECbiomass = 21 mg/L

72 hour LOECbiomass = 37 mg/L

72 hour EC50biomass = 48 mg/L


Acute toxicity to the giant water flea (crustacean) Daphnia magna


48 hour EC50 >120 mg/L
48 hour NOEC = 120 mg/L


Fish early-life stage toxicity with fathead minnow, Pimephales promelas


32 day NOEC = 1.0 mg/L

32 day LOEC > 1.0 mg/L based on hatch, survival, standard length, and dry weight


Long-term toxicity to Daphnia magna


21 day NOAEC = 10 mg/L based on reproduction and length


Long-term toxicity to the sediment dwelling midge, Chironomus riparius 


28 day NOEC = 150 mg/kg dry sediment

28 day LOEC > 150 mg/kg dry sediment, based on emergence, development rate and sex ratio


EC50 the concentration of the test substance that results in a 50% effect

NOEC no observed effect concentration

NOAEC no observed adverse effect concentration

LOEC lowest observed effect concentration

PNEC (Predicted No Effect Concentration)

Long-term tests have been undertaken for species from three trophic levels, based on internationally accepted guidelines. Therefore, the PNEC is based on the results from the chronic toxicity to fathead minnow (Pimephales promelas), the most sensitive species, and an assessment factor of 10 is applied, in accordance with ECHA guidance (Ref. 10).

PNEC = 1000/10 µg/L = 100 µg/L

Environmental risk classification (PEC/PNEC ratio)

PEC = 0.0032 µg/L

PNEC = 100 µg/L

PEC/PNEC = 3.2 x 10-5

The PEC/PNEC ratio is < 0.1  which justifies the phrase: ‘Use of dapagliflozin has been considered to result in insignificant environmental risk’.

In Swedish: “Användning av dapagliflozin har bedömts medföra försumbar risk för miljöpåverkan” under the heading “Miljörisk”.

Environmental Fate Data

Study Type




Aerobic biodegradation


11% after 28 days.

Not readily biodegradable


Adsorption/desorption to sludge

OPPTS guideline 835.1110

Kd(ads) = 51 L/Kg

Koc = 138 L/Kg


Aerobic transformation in aquatic sediment systems


  • Mass balance 83-120% of applied radioactivity

  • The half-lives (DT50) in the water 6.0 – 8.7 days

  • The half-lives (DT50) in the sediment ranged 95 - 128 days 

  • Extensive mineralisation (14CO2 formation) observed in both high and low organic matter vessels with 35 and 68% of the applied radioactivity after 99 days

  • Kdsediment = 12 kg/L, based on measured partitioning at 8 days


Kd Distribution coefficient for adsorption

Koc Organic carbon normalized adsorption coefficient

Biotic degradation

Dapagliflozin is not readily biodegraded as measured in an OECD 301F study (Ref 11), but based on the Aerobic Transformation in Aquatic Sediment System OECD 308 (Ref 12), dapagliflozin slowly degrades in the environment.

The degradation of dapagliflozin in aquatic sediment systems was assessed according to the OECD 308 Test Guideline. In this test two different sediments were used, one with high organic matter (HOM) and one with low organic matter content (LOM). Radiolabelled test substance was dosed into the overlying water and the subsequent dissipation from the water phase, and partitioning and/or degradation in the sediment, was observed over a 99 day test period. Since mineralisation was very strong the test vessels were kept to monitor CO2 production over 148 days.

The partitioning of dapagliflozin in aquatic sediment systems appears to stop at Day 8 and no further significant amounts of radioactivity moved into the sediment. Afterwards degradation and mineralisation took place, apparently in the water phase.

Transformation of dapagliflozin into a possible seven transformation products was rapid as was partitioning to the sediment. Extensive mineralisation was seen in both the high and low organic matter sediment vessels with 35 and 68%, respectively of the applied radioactivity produced as CO2 after 99 days.

Following extensive sediment extration, using a variety of organic solvents of varying polarity, a significant proportion of the applied radioactivity, 44% in the high organic matter system and 24% in the low organic matter system, on Day 99, remained as non-extractable residue (NER). At Day 99 the amount of applied radioactivity removed from the total system as 14CO2 and NER, accounted for 79 and 92% in the high and low organic matter sediment vessels, respectively. Accordingly the half life of dapagliflozin in both aquatic sediment systems is <120 days.

Based on the data above dapagliflozin has been assigned the risk phrase: ‘Dapagliflozin is slowly degraded in the environment.’

In Swedish: “Dapagliflozin bryts ned långsamt i miljön.” under the heading “Nedbrytning”.


Dapagliflozin is not ionisable within the environmentally relevant pH range (estimated pKa = 12.6). The octanol-water partition coefficient was 2.34, measured at pH 7.4. Since Log POW < 4, dapagliflozin has low potential to bioaccumulate and the phrase “Dapagliflozin has low potential for bioaccumulation” is assigned.

In Swedish:Dapagliflozin har låg potential att bioackumuleras” under the heading “Bioackumulering”.

Physical Chemistry Data

Study Type




Octanol-water distribution coefficient

OECD107, Shake flask

log Pow = 2.34 at pH 7


Water solubility

OECD105, Shake flask

pH 5 = 720 mg/L

pH 7 = 538 mg/L

pH 9 = 946 mg/L




<10% after 5 days at 50°C (pH 5 & 7)

11.5 % after 5 days at 50°C (pH 9)

at 25°C ≥ 1 year




  1. Environmental Classification of Pharmaceuticals in www.fass.se – Guidance for Pharmaceutical Companies. (2012 v 2.0).

  2. Kasichayanula, S., Liu, X., LaCreta, F. et al. 2014. Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2. Clin Pharmacokinet 53: 17-27

  3. Mass balance and metabolism of [14C]BMS-512148 in healthy male subjects. Bristol-Myers Squibb, Princeton, New Jersey 08543, USA. Protocol Number MB102006. November 2006

  4. Dapagliflozin: Effect on the respiration rate of activated sludge. BLS8577/B. Brixham Environmental Laboratory, Brixham, UK. October 2008.

  5. Dapagliflozin: Toxicity to the green alga Pseudokirchneriella subcapitata. BL8587/B. Brixham Environmental Laboratory, Brixham, UK. December 2008.

  6. Dapagliflozin: Acute toxicity to Daphnia magna. BL8590/B. Brixham Environmental Laboratory, Brixham, UK. September 2008.

  7. Dapagliflozin: Determination of effects on the Early-Life Stage of the fathead minnow (Pimephales promelas). BL8638/B. Brixham Environmental Laboratory, Brixham, UK. December 2008.

  8. Dapagliflozin: Chronic toxicity to Daphnia magna. BL8622/B. Brixham Environmental Laboratory, Brixham, UK. May 2009.

  9. [14C]Dapagliflozin: Effects in sediment on emergence of the midge, Chironomus riparius. BL8661/B. Brixham Environmental Laboratory, Brixham, UK. March 2009.

  10. ECHA (European Chemicals Agency) 2008. Guidance on information requirements and chemical safety assessment. Chapter R.10: Characterisation of dose [concentration]-response for environment http://guidance.echa.europa.eu/docs/guidance_document/information_requirements_en.htm

  11. Dapagliflozin: Determination of 28 day ready biodegradability. Report No. BL8586/B. Brixham Environmental Laboratory, Brixham, UK. July 2008.

  12. Dapagliflozin: Activated sludge sorption isotherm. Report No. BL8614/B. Brixham Environmental Laboratory, Brixham, UK. August 2008.

  13. Dapagliflozin: Aerobic transformation in aquatic sediment systems. BL8594/B. Brixham Environmental Laboratory, Brixham, UK. February 2009.

  14. Dapagliflozin: Determination of 1-octanol/water partition coefficient. Report No. BL8585/B. Brixham Environmental Laboratory, Brixham, UK. June 2008.

  15. Dapagliflozin: Determination of Water Solubility Shake Flask Method. Report No. BLS3433/B. Brixham Environmental Laboratory, Brixham, UK. June 2008.

  16. Dapagliflozin: Hydrolysis as a function of pH - preliminary study results summary. BLS3434/B. Brixham Environmental Laboratory, Brixham, UK. July 2008.